Cardiomyocyte Drug Discovery


Contact Us

Literature

Cardiac Drug Discovery

Heart failure affects more than 23 million patients worldwide, with high mortality despite decades of therapeutic development. Many treatments improve cardiac function but introduce unwanted side effects.

Human iPSC-derived cardiomyocytes (hiPSC-CMs) provide a human-relevant model to evaluate both efficacy and cardiotoxicity of new therapies, including inotropic compounds. The xCELLigence RTCA CardioECR system enables real-time monitoring of cardiomyocyte excitation–contraction coupling for more predictive drug discovery.

Easy, Flexible Workflow

No cell labeling required. Simply seed cells, monitor function in real time, and evaluate drug mechanism, efficacy, and toxicity in cardiomyocytes.

Application Note: 
xCELLigence RTCA CardioECR System ​​​​​​for cardiac safety and toxicity assessment

Assessment of Inotropic Compounds

Traditional inotropic and whole-organ assays are labor-intensive, costly, and low throughput, while animal models may lack human translational relevance. Functionally immature hiPSC-CMs further complicate inotropy testing.

Agilent’s electrical pacing protocol drives functional maturation of hiPSC-CMs, enabling reliable assessment of both positive and negative inotropic responses in a scalable in vitro system.

Application Notes

A Real-Time Impedance Analysis Instrument for Cardiac Safety and Toxicity Assessment

Assessment of Cardiomyocyte Disease Models Using the xCELLigence CardioECR System

Using the xCELLigence RTCA ePacer for Functional Maturation of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes 

Publications

  1. Inhibition of profibrotic signalling enhances the 5-azacytidine-induced reprogramming of fibroblasts into cardiomyocytes.
    Jia Y, Chang Y, Sun P, Li H, Guo Z. Int J Biochem Cell Biol. 2020 Feb 27;122:105733 (Xinxiang Medical University, PR China.) 
  2. High throughput physiological screening of iPSC-derived cardiomyocytes for drug development.
    Del Álamo JC, Lemons D, Serrano R, Savchenko A, Cerignoli F, Bodmer R, Mercola M.  Biochim Biophys Acta. 2016 Jul;1863(7 Pt B):1717-27.  (University of California, San Diego. USA) 
  3. Cardamonin, a Novel Antagonist of hTRPA1 Cation Channel, Reveals Therapeutic Mechanism of Pathological Pain.
    Wang S, Zhai C, Zhang Y, Yu Y, Zhang Y, Ma L, Li S, Qiao Y. Molecules. 2016 Aug 29;21(9). (Beijing University of Chinese Medicine, PR China)
  4. Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes.
    Eldridge S, Guo L, Mussio J, Furniss M, Hamre J 3rd, Davis M. Toxicol Sci. 2014 Oct;141(2):547-59. (National Cancer Institute, USA)

For Research Use Only. Not for use in diagnostic procedures.